From Financial Modeling Prep: 2025-02-14 07:00:02

Moderna’s consensus price target has dropped significantly from $119.26 to $47.5, reflecting a cautious outlook from analysts. The company reported higher-than-expected revenue of $1 billion for Q4 but faced a GAAP net loss of $1.1 billion, including non-cash charges. Revenue forecast for 2025 is between $1.5 billion and $2.5 billion, driven by new product development. Analysts are closely monitoring the company’s performance and potential, with a price target of $155 set by Deutsche Bank.



Read more at Financial Modeling Prep:: Moderna, Inc. (NASDAQ:MRNA) Faces Challenges and Opportunities in Biotech Sector